DE69922206D1 - Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere - Google Patents
Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomereInfo
- Publication number
- DE69922206D1 DE69922206D1 DE69922206T DE69922206T DE69922206D1 DE 69922206 D1 DE69922206 D1 DE 69922206D1 DE 69922206 T DE69922206 T DE 69922206T DE 69922206 T DE69922206 T DE 69922206T DE 69922206 D1 DE69922206 D1 DE 69922206D1
- Authority
- DE
- Germany
- Prior art keywords
- hydroxyacids
- oligomers
- linear
- ketone
- cyclic oligomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 abstract 5
- REKYPYSUBKSCAT-UHFFFAOYSA-N 3-hydroxypentanoic acid Chemical compound CCC(O)CC(O)=O REKYPYSUBKSCAT-UHFFFAOYSA-N 0.000 abstract 4
- 125000004122 cyclic group Chemical group 0.000 abstract 4
- 150000002576 ketones Chemical class 0.000 abstract 4
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 235000015872 dietary supplement Nutrition 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 abstract 1
- OXSSIXNFGTZQMZ-UHFFFAOYSA-N 3-hydroxyheptanoic acid Chemical compound CCCCC(O)CC(O)=O OXSSIXNFGTZQMZ-UHFFFAOYSA-N 0.000 abstract 1
- HPMGFDVTYHWBAG-UHFFFAOYSA-N 3-hydroxyhexanoic acid Chemical compound CCCC(O)CC(O)=O HPMGFDVTYHWBAG-UHFFFAOYSA-N 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 150000001261 hydroxy acids Chemical class 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000003880 negative regulation of appetite Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 235000016236 parenteral nutrition Nutrition 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9376098P | 1998-07-22 | 1998-07-22 | |
| US93760P | 1998-07-22 | ||
| PCT/US1999/016614 WO2000004895A2 (en) | 1998-07-22 | 1999-07-22 | Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69922206D1 true DE69922206D1 (de) | 2004-12-30 |
| DE69922206T2 DE69922206T2 (de) | 2005-11-24 |
Family
ID=22240563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69922206T Expired - Lifetime DE69922206T2 (de) | 1998-07-22 | 1999-07-22 | Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6380244B2 (de) |
| EP (1) | EP1098655B1 (de) |
| JP (2) | JP2002521330A (de) |
| AT (1) | ATE283056T1 (de) |
| AU (1) | AU755348B2 (de) |
| CA (1) | CA2338090C (de) |
| DE (1) | DE69922206T2 (de) |
| ES (1) | ES2234276T3 (de) |
| MX (1) | MXPA01000632A (de) |
| WO (1) | WO2000004895A2 (de) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323237B1 (en) | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| US20090253781A1 (en) * | 2002-05-24 | 2009-10-08 | Btg International Limited | Therapeutic compositions |
| WO2000015216A1 (en) * | 1998-09-15 | 2000-03-23 | Btg International Limited | Therapeutic compositions (ii) |
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| US20020006959A1 (en) | 2000-05-01 | 2002-01-17 | Henderson Samuel T. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism |
| US6410063B1 (en) | 2000-06-13 | 2002-06-25 | Hill's Pet Nutrition, Inc. | Composition and method |
| US7700074B2 (en) * | 2002-02-07 | 2010-04-20 | Pettegrew Jay W | Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism |
| US7407778B2 (en) * | 2002-02-07 | 2008-08-05 | Pettegrew Jay W | Compounds, compositions and methods for treating neuropsychiatric disorders |
| US20060257842A1 (en) * | 2003-05-29 | 2006-11-16 | Pettegrew Jay W | Cryopreservation media and molecules |
| EP1641806B1 (de) * | 2003-05-29 | 2009-07-29 | Jay W. Pettegrew | Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen |
| AU2004245567B2 (en) | 2003-06-03 | 2011-06-23 | Oxford University Innovation Limited | Nutritional supplements and therapeutic compositions comprising (R)-3-hydroxybutyrate derivatives |
| EP1661574B1 (de) * | 2003-09-01 | 2017-04-19 | Earthus, Inc. | Beta-hydroxy-kurz- bis mittelkettiges fettsäure-polymer |
| GB0420856D0 (en) * | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
| EP1778213B1 (de) * | 2004-07-16 | 2017-04-05 | BTG International Limited | Verfahren zur herstellung oligomerer verbindungen |
| WO2006020179A2 (en) * | 2004-07-20 | 2006-02-23 | Ketocytonyx Inc. | Oligomeric ketone compounds |
| US20070225252A1 (en) * | 2004-07-23 | 2007-09-27 | Gross Richard A | Ketogenic Saccharides |
| EP1793813A4 (de) * | 2004-09-21 | 2011-05-18 | Btg Int Ltd | Behandlung von adhd |
| EP1796658B1 (de) * | 2004-09-21 | 2016-03-30 | BTG International Limited | Dopaminerge mimetika |
| GB0427145D0 (en) * | 2004-12-10 | 2005-01-12 | Ketocytonyx Inc | Compositions for use in surgery |
| CN100344280C (zh) * | 2005-08-01 | 2007-10-24 | 清华大学 | 3－羟基丁酸及其衍生物的新用途 |
| HUE035852T2 (en) * | 2006-04-03 | 2018-05-28 | Accera Inc | Use of ketogen compounds to treat memory decline |
| WO2008005818A1 (en) * | 2006-06-30 | 2008-01-10 | Stepan Co | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
| US8758740B2 (en) | 2007-03-30 | 2014-06-24 | Earthus, Inc | Composition for promoting ketone body production |
| KR101335021B1 (ko) | 2007-07-31 | 2013-12-12 | 액세라인크 | 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물 |
| EP2240017B1 (de) * | 2008-01-04 | 2019-03-13 | Oxford University Innovation Limited | Ketonkörper und ketonkörperester als blutfettsenkende mittel |
| KR101734152B1 (ko) | 2008-07-03 | 2017-05-11 | 액세라인크 | 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체 |
| US8105809B2 (en) * | 2008-07-03 | 2012-01-31 | Accera, Inc. | Enzymatic synthesis of acetoacetate esters and derivatives |
| US8642654B2 (en) * | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
| AU2013337308B2 (en) | 2012-11-05 | 2018-06-21 | Tdeltas | Ketone bodies to protect tissues from damage by ionizing radiation |
| GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
| GB2515603B (en) | 2013-03-14 | 2015-10-14 | Isis Innovation | Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate |
| BR112015024186B1 (pt) * | 2013-03-19 | 2023-05-09 | University Of South Florida | Composições e métodos para produção de cetose de elevação e manutenção |
| CA2973342A1 (en) * | 2014-01-13 | 2015-10-15 | University Of South Florida | Methods of sustaining dietary ketosis and its effects on lipid profile |
| US10137102B2 (en) | 2014-07-21 | 2018-11-27 | Oulun Yliopisto | Oligomeric forms of 3-hydroxybutyrate |
| US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
| US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
| US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
| US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
| US11173138B2 (en) * | 2016-04-19 | 2021-11-16 | Keto Patent Group, Inc. | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
| US11337945B2 (en) | 2016-06-01 | 2022-05-24 | Keto Innovations, Llc | C5 ketone compositions, and related methods, for therapeutic and performance supplementation |
| US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
| EP3558291A1 (de) * | 2016-12-23 | 2019-10-30 | Katholieke Universiteit Leuven | 3-hydroxybutyrat allein oder in kombination zur verwendung bei behandlungen in der intensivpflege |
| US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
| GB201715654D0 (en) | 2017-09-27 | 2017-11-08 | Tdeltas Ltd | Method of treatment |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| IT201800003441A1 (it) | 2018-03-12 | 2019-09-12 | Bio On Spa | Poliidrossialcanoati per l’uso nella prevenzione del cancro colorettale. |
| US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
| US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
| CA3022995C (en) * | 2018-06-12 | 2019-10-15 | Ketofibe (9211-3133 Quebec Inc.) | Novel ketogenic compounds, compositions, methods and use thereof |
| IT201800007524A1 (it) * | 2018-07-26 | 2020-01-26 | Bio-On Spa | Poliidrossialcanoati per l'uso nella prevenzione o nel trattamento di una condizione di sovrappeso o di obesita', ovvero di disfunzioni metaboliche correlate a tale condizione. |
| US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| CN110776425B (zh) * | 2019-10-23 | 2021-02-26 | 清华大学 | 一种(r)-3-羟基丁酸及其低聚物的制备方法 |
| BR112022017809A2 (pt) * | 2020-03-05 | 2023-01-10 | Vitanav Inc | Composição de ácido (d)-ss-hidroxibutírico, ácido (d)-ss-hidroxivalérico e (d)-1,3-butanodiol como suplemento nutricional e agente terapêutico |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4329359A (en) | 1979-12-28 | 1982-05-11 | University Of Kentucky Research Foundation | Method for improving the metabolic stability and survival of newborn pigs |
| US4423072A (en) | 1979-12-28 | 1983-12-27 | The University Of Kentucky Research Foundation | Method for improving the metabolic stability and survival of neonatal pigs |
| FR2486072A1 (fr) * | 1980-07-03 | 1982-01-08 | Solvay | Procede pour la fabrication de l'acide b-hydroxybutyrique et de ses oligocondensats |
| US4563354A (en) | 1983-10-26 | 1986-01-07 | Kabivitrum Ab | Oil-in-water emulsion for parenteral administration |
| AU602772B2 (en) | 1987-04-22 | 1990-10-25 | Baxter International Inc. | Lipid emulsion and method for intravenous infusion |
| BE1001209A3 (fr) | 1987-11-19 | 1989-08-22 | Solvay | Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol. |
| US5126373A (en) * | 1987-11-19 | 1992-06-30 | Henri Brunengraber | Composition for parenteral and oral nutrition |
| SE8705035L (sv) | 1987-12-17 | 1989-06-18 | Kaernerud Lars Haelsoprod | Anvaendning av alkylglycerol |
| CA1334575C (en) | 1988-07-26 | 1995-02-28 | Atsushi Hiraide | Substitution fluid preparation comprising 3-hydroxybutyric acid (beta-hydroxybutyric acid) and its salts |
| SE8803142L (sv) | 1988-09-07 | 1990-03-08 | Kabivitrum Ab | Nya energisubstrat |
| SE8803141L (sv) | 1988-09-07 | 1990-03-08 | Kabivitrum Ab | Naeringsmedel foer maenniskor och djur |
| ATE98479T1 (de) | 1989-03-30 | 1994-01-15 | Kabivitrum Ab | Arznei-lipid-zusammensetzung fuer parenterale nahrung. |
| JP2885261B2 (ja) * | 1993-05-17 | 1999-04-19 | 三菱瓦斯化学株式会社 | ３−ヒドロキシ酪酸のオリゴマー及びその塩からなる輸液製剤 |
| WO1995009144A1 (en) | 1993-09-30 | 1995-04-06 | Eastman Chemical Company | Nutritive water soluble glycerol esters of hydroxy butyric acid |
| WO1995018781A1 (en) | 1994-01-06 | 1995-07-13 | Metabolix, Inc. | Methods for synthesizing oligomers containing hydroxy acid units |
| US6083729A (en) | 1995-10-26 | 2000-07-04 | Metabolix, Inc. | Methods for isolating polyhydroxyalkanoates from plants |
| JP4598203B2 (ja) | 1995-12-01 | 2010-12-15 | ビーティージー・インターナショナル・リミテッド | 脳機能改善剤 |
| KR100839689B1 (ko) * | 1997-03-17 | 2008-06-18 | 비티지 인터내셔널 리미티드 | 치료용 조성물 |
| ATE227088T1 (de) | 1998-01-07 | 2002-11-15 | Metabolix Inc | Tierfutterzusammensetzungen |
-
1999
- 1999-07-22 AT AT99935846T patent/ATE283056T1/de not_active IP Right Cessation
- 1999-07-22 CA CA002338090A patent/CA2338090C/en not_active Expired - Fee Related
- 1999-07-22 EP EP99935846A patent/EP1098655B1/de not_active Expired - Lifetime
- 1999-07-22 WO PCT/US1999/016614 patent/WO2000004895A2/en active IP Right Grant
- 1999-07-22 DE DE69922206T patent/DE69922206T2/de not_active Expired - Lifetime
- 1999-07-22 MX MXPA01000632A patent/MXPA01000632A/es unknown
- 1999-07-22 JP JP2000560888A patent/JP2002521330A/ja not_active Withdrawn
- 1999-07-22 US US09/359,086 patent/US6380244B2/en not_active Expired - Lifetime
- 1999-07-22 ES ES99935846T patent/ES2234276T3/es not_active Expired - Lifetime
- 1999-07-22 AU AU51231/99A patent/AU755348B2/en not_active Ceased
-
2011
- 2011-10-21 JP JP2011231730A patent/JP2012072148A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1098655A2 (de) | 2001-05-16 |
| JP2002521330A (ja) | 2002-07-16 |
| ES2234276T3 (es) | 2005-06-16 |
| CA2338090A1 (en) | 2000-02-03 |
| ATE283056T1 (de) | 2004-12-15 |
| JP2012072148A (ja) | 2012-04-12 |
| US20020013339A1 (en) | 2002-01-31 |
| MXPA01000632A (es) | 2002-05-06 |
| EP1098655B1 (de) | 2004-11-24 |
| DE69922206T2 (de) | 2005-11-24 |
| AU755348B2 (en) | 2002-12-12 |
| WO2000004895A3 (en) | 2000-04-27 |
| CA2338090C (en) | 2009-07-14 |
| US6380244B2 (en) | 2002-04-30 |
| WO2000004895A2 (en) | 2000-02-03 |
| AU5123199A (en) | 2000-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69922206D1 (de) | Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere | |
| Guo et al. | The role of nutrition in the prevention and intervention of type 2 diabetes | |
| Bistrian et al. | Effect of a protein-sparing diet and brief fast on nitrogen metabolism in mildly obese subjects | |
| Marckmann | Fishing for heart protection | |
| KR100839689B1 (ko) | 치료용 조성물 | |
| Hayes et al. | Effect of whey protein isolate on strength, body composition and muscle hypertrophy during resistance training | |
| JP2002521330A5 (de) | ||
| Bistrian | Hyperglycemia and infection: which is the chicken and which is the egg? | |
| Man et al. | The roles of gut microbiota and circadian rhythm in the cardiovascular protective effects of polyphenols | |
| Morisco et al. | Foods and liver health | |
| Chaldakov et al. | Comment on: Krabbe KS, Nielsen AR, Krogh-Madsen R et al (2007) Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50: 431–438 | |
| Van Wyk et al. | Case Discussion: The Use of Very Low Calorie Diets in the Management of Type 2 Diabetes Mellitus | |
| Lee | The Assessment of Dietary interventions on Stem Cell Fate, Homeostatic Mechanisms, and Disease | |
| Hellerstein | Mitigating factors and metabolic mechanisms in fructose-induced nonalcoholic fatty liver disease: the next challenge12 | |
| Terent et al. | ACTIVITY OF ASPARTATE AMINOTRANSFERASE IN THE TISSUES OF THE DUODENUM IN RABBITSIN DIFFERENT PHASES OF POSTNATAL ONTOGENESIS | |
| Lu et al. | The effects of nutritional ketosis induced by Bigu-herbs regimen and ketogenic diet on diseases and aging | |
| Zhang | Effect of High-fat Low-carbohydrate Diet on the Structure of Intestinal Flora in T2DM Patients: A Narrative Review | |
| Kwiendacz et al. | An unusual use of personal insulin pump by a patient with type 1 diabetes on a ketogenic diet—a case report | |
| Brader et al. | MeGa doses of ViTaMiN c | |
| Zhang | Ketogenic Diet: Effective Prevention and Treatment for type II diabetes and Obesity | |
| Galali et al. | The impact of ketogenic diet on some metabolic and non‐metabolic diseases: Evidence from human and animal model experiments | |
| Hite et al. | Low-carbohydrate diet scores and risk of type 2 diabetes in men | |
| Herber et al. | Effects of Aging on Skeletal Muscle Hypertrophy | |
| Peter et al. | Need for high protein diet during metabolic stress | |
| WO2021058514A1 (en) | Compositions and methods using adenosylcobalamin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |